在坦桑尼亚进行的合成疟疾疫苗SPf66试验：基本原理与设计

A trial of the synthetic malaria vaccine SPf66 in Tanzania: rationale and design.

作者信息

Alonso P L, Tanner M, Smith T, Hayes R J, Schellenberg J A, Lopez M C, Bastos de Azevedo I, Menendez C, Lyimo E, Weiss N

机构信息

Epidemiology Research Unit, Fundacio per a la Recerca Biomedica, Barcelona, Spain.

出版信息

Vaccine. 1994 Feb;12(2):181-6. doi: 10.1016/0264-410x(94)90058-2.

DOI:10.1016/0264-410x(94)90058-2

PMID:8147101

Abstract

The development of a safe, affordable and effective malaria vaccine to form part of control schemes in malaria endemic countries is a priority for researchers and public health officials. SPf66 is the first malaria vaccine to have shown partial protection against natural challenge in a phase III trial carried out in a hypoendemic area of Colombia. This paper describes the rationale and design of the first field trial of SPf66 outside South America, and the first to be conducted in an area of high perennial transmission.

摘要

开发一种安全、可负担且有效的疟疾疫苗，使其成为疟疾流行国家防控计划的一部分，这是研究人员和公共卫生官员的首要任务。SPf66是第一种在哥伦比亚低流行地区进行的III期试验中显示出对自然感染具有部分保护作用的疟疾疫苗。本文描述了SPf66在南美洲以外首次进行现场试验的基本原理和设计，也是首次在常年高传播地区进行的试验。